Alopecia areata
☆ I 2022 Stiftung Warentest-resultaterne fra Tyskland var forbrugernes tilfredshed med ModelDerm kun lidt lavere end med betalte telemedicinske konsultationer.
Alopecia areata ses på bagsiden af hovedbunden. I typiske tilfælde dukker den pludselig op med en helt glat overflade og en størrelse på 2-3 cm.
relevance score : -100.0%
ReferencesAlopecia areata er en tilstand, hvor dit immunsystem angriber hårsækkene, hvilket fører til midlertidigt hårtab uden ardannelse. Tilstanden kan vise sig som pletter af hårtab eller som et generelt tab på hele hovedbunden eller kroppen og rammer omkring 2 % af befolkningen på et tidspunkt i deres liv. Den underliggende årsag synes at være et sammenbrud i den naturlige beskyttelse omkring hårsækkene.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Alopecia areata er en tilstand, hvor immunsystemet angriber hårsækkene, hvilket forårsager hårtab i hovedbunden og andre behårede dele af kroppen. Tilstanden påvirker omkring 2 % af verdens befolkning. Selvom den kan forekomme i alle aldre, er den hyppigere hos børn end hos voksne (1,92 % vs. 1,47 %). Kvinder, især dem over 50 år, har en tendens til at opleve den oftere end mænd. Injektion af kortikosteroider direkte i de berørte områder har vist bedre resultater end topisk anvendelse.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
Alopecia areata menes at være en autoimmun sygdom, der påvirker immunsystemet i hårsækkene. Den underliggende mekanisme indebærer, at kroppen ikke kan genkende sine egne celler, hvilket fører til immunmedieret ødelæggelse af hårsækkene.
○ Behandling ― OTC-lægemidler
Nogle personer med mild alopecia areata kommer sig inden for et år uden behandling, men de fleste oplever gentagelser på andre steder i hovedbunden.
#Hydrocortisone cream
○ Behandling
Intralesionale steroidinjektioner er den mest effektive behandling. Immunterapi kan forsøges, hvis store områder af hovedbunden er påvirket.
#Triamcinolone intralesional injection
#DPCP immunotherapy